Skip to main content
. Author manuscript; available in PMC: 2013 Mar 15.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2011 Jul 19;82(4):1367–1375. doi: 10.1016/j.ijrobp.2011.05.027

Table 2.

Pathologic Complete Response Rate First 48 Evaluable Patients on Each Arm PRIMARY ENDPOINT

Capecitabine/Irinotecan/RT
(n=48)
Capecitabine/Oxaliplatin/RT
(n=48)
Number Evaluable 48 48
Number with Pathologic Complete Response 5 10
Percentage with Pathologic Complete Response 10.4 20.8
Exact 95% Confidence Interval for Percentage with Pathologic Complete Response (3.5, 22.7) (10.5, 35.0)